Mannkind (MNKD) Total Current Liabilities (2010 - 2026)
Mannkind (MNKD) posted quarterly Total Current Liabilities of $134.6 million for Q1 2026, up 16.06% year-over-year from $115.9 million in Q1 2025, and down 21.32% quarter-over-quarter from $171.0 million in Q4 2025.
Mannkind (MNKD) Total Current Liabilities (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has reported Total Current Liabilities for 17 consecutive years, with $134.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 16.06% year-over-year to $134.6 million; the TTM figure through Mar 2026 stood at $134.6 million (up 16.06% YoY), while the FY2025 annual figure was $171.0 million, up 108.99% from the prior year.
- Total Current Liabilities fell to $134.6 million in Q1 2026 per MNKD's latest filing, from $171.0 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $171.0 million in Q4 2025 and bottomed at $53.5 million in Q1 2022.
- Historically, Total Current Liabilities has averaged $93.9 million across 5 years, with a median of $96.4 million in 2023.
- Annual changes were most pronounced in 2022 — Total Current Liabilities dropped 26.84% — and 2025, when it jumped 108.99%.
- Mannkind's Total Current Liabilities stood at $67.3 million in 2022, then soared by 54.73% to $104.1 million in 2023, then slipped by 21.41% to $81.8 million in 2024, then jumped by 108.99% to $171.0 million in 2025, then dropped by 21.32% to $134.6 million in 2026.
- Business Quant data shows MNKD's Total Current Liabilities at $134.6 million in Q1 2026, $171.0 million in Q4 2025, and $109.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Mannkind | 1.19 Bn | 1.08 Bn | 94.97 Mn | 142.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 142.90 Mn |
| Mar 31, 2026 | 134.56 Mn |
| Dec 31, 2025 | 171.03 Mn |
| Sep 30, 2025 | 109.13 Mn |
| Jun 30, 2025 | 111.83 Mn |
| Mar 31, 2025 | 115.94 Mn |
| Dec 31, 2024 | 81.84 Mn |
| Sep 30, 2024 | 72.10 Mn |
| Jun 30, 2024 | 80.01 Mn |
| Mar 31, 2024 | 99.90 Mn |
| Dec 31, 2023 | 104.13 Mn |
| Sep 30, 2023 | 96.37 Mn |
| Jun 30, 2023 | 96.97 Mn |
| Mar 31, 2023 | 81.85 Mn |
| Dec 31, 2022 | 67.30 Mn |
| Sep 30, 2022 | 59.60 Mn |
| Jun 30, 2022 | 59.56 Mn |
| Mar 31, 2022 | 53.49 Mn |
| Dec 31, 2021 | 48.35 Mn |
| Sep 30, 2021 | 50.03 Mn |